New highly sensitive CFSE T cell proliferation assays launched by ProImmune

ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

Combined with ProImmune’s unique cell-free HLA-peptide binding assays for more than 50 class II HLA alleles, these new assays enable the creation of a detailed profile of the helper T cell immune response to one or more drug leads.

Unlike traditional assays, which are based on radioactive thymidine incorporation, ProImmune’s new assays utilise powerful flow cytometry methods, enabling accurate determination of the percentage of proliferating CD4-positive cells and detailed phenotyping of T cell responses with significantly improved overall sensitivity.

Dr. Nikolai Schwabe, CEO of ProImmune, said: "Our customers have come to expect ProImmune to deliver technology leadership without compromise. The launch of our CFSE T cell proliferation assays joins with our unequalled capability in class II HLA binding assays, delivering the most powerful in vitro assay platform on the market for assessing drug immunogenicity risk.”




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines